FDAsafety guidance83% confidence
January - March 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as pharmaceutical companies in pain management.
Regulatory Analysis
January - March 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Supporting Context
- Therapeutic area
- Gynecology · Dysmenorrhea
- Sub-indication
- Pain
Related signal: Study on SuJok Therapy for Primary Dysmenorrhea Shows Potential Benefits